Pharmaceutical composition for treating gastroduodenal ulcer, possessing immunomodulatory, antiviral, antibacterial, anti-inflammatory, antioxidant and regenerative effect in form of tablets, capsules or gel

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.

EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.

6 cl, 5 ex

 

The invention relates to pharmaceutical industry and medicine, in particular to pharmaceutical compositions for the treatment of gastric ulcer and/or duodenal ulcers

Peptic ulcer and duodenal ulcer is a leading pathology in diseases of the gastrointestinal tract. Medical treatment involves exposure to pathogenic components and the clinical symptoms of peptic ulcer disease and includes an introduction into the body of the patient medicines, neutralizing hydrochloric acid with anti-inflammatory, antispasmodic, analgesic, sedative and coating the mucous membrane properties.

Widely known drugs for treatment of peptic ulcer of stomach and duodenum with these tools.

Known protivozachatochnye means that suppress the action of hydrochloric acid and pepsin, which include blockers of H2-histamine receptors, blockers of H+/K+-ATPase, blockers, muscarinic receptors, ganglioblokatory blockers phosphatidylinositol cycle blockers gastronomic receptor blockers secretion of pepsin, blockers, carbonic anhydrase (EN 2060732, AK 31/18, 1996).

It is widely known use of H2-receptor blockers of histamine, which are powerful anti-ulcer with what edstam, leading to decreased secretion of pepsin and hydrochloric acid at 40-50% and providing an analgesic effect. Blockers of H2-histamine receptors are cimetidine, ranitidine, famotidine. Famotidine has the most powerful antisecretory action. Treatment of patients with peptic ulcer disease includes oral administration of the drug during the month, followed by a supporting therapy for several years (Goncharik I. I. Diseases of the stomach and intestines, Minsk, High school, 1994, S. 67-69).

Lack of drug therapy with H2-receptor blockers histamine is the duration of the treatment. When drug is withdrawn, most patients have a relapse, and therefore, maintenance therapy should be done in a few years.

Half of the patients with continuous drug after 3 years there is a relapse of the disease. In addition, long-term use of the drug causes adverse reactions in some patients: diarrhea, nausea, and headaches. The drug is contraindicated in patients with impaired liver and kidneys.

Widely known from blockers H+/K+-ATPase omeprazole with strong and long-lasting depressing effect on basal and stimulated secretion of hydrochloric acid. Omeprazole is the drug of choice for treatment of patients resistant to therapy blocker is mi H2-histamine receptors (Goncharik And. And. Diseases of the stomach and intestines, Minsk, High school, 1994, S. 70).

However, treatment with omeprazole is long. Inhibition of production of hydrochloric acid may have adverse effects: growth in the stomach potentially harmful microflora, increasing the number of cells secreting gastrin. In addition, observed in patients with other adverse reactions such as dizziness, fatigue, visual disturbances.

It is known that in the conservative treatment of peptic ulcer disease has a significant place anticholinergic that blocks muscarinic receptors peptic glands and muscle membranes of the digestive tract. They inhibit gastric motility, have antispasmodic properties and contribute to the healing of ulcers. The most common anticholinergic atropine sulfate, platifillina hydrotartrate, metacin, Pro-bantin, aprofen, glycopyrronium, extract of belladonna (Person-Russ Y. I., Russ E. C. Gastro-duodenal ulcers. L., Medicine, 1978, S. 176-188).

However, the drug is toxic, poorly tolerated, causes heart palpitations, and dry mouth.

Known complex drugs for treatment of peptic ulcer of stomach and duodenum in the form of tablets, capsules or gel (EN 2143899, AK 31/43 2000; EN 2060732, AK 31/18, 1996; EN 2301662, AK 9/26, 31/4439 2002).

Known complex drugs for treatment of peptic ulcer disease is ludka and duodenum in the form of tablets, capsules or gel (EN 2143899, AK 31/43 2000; EN 2060732, AK 31/18, 1996; EN 2301662, AK 9/26, 31/4439 2002).

Known complex drugs are not effective enough. They do not provide a 100% healing of the ulcer, there is the occurrence of relapses and side effects.

Closest to the claimed invention, the essential features and the achieved result is a pharmaceutical composition for the treatment of gastric ulcer and duodenal ulcer, containing rabeprazole as an active drug substance, as excipients, fillers (diluents), binders, disintegrating agents, sliding, lubricating, binders, inert carriers (EN 2414889, AK 9/48, 31/4439 2011).

The disadvantage of this arrangement is time-consuming manufacturing process, which consists of several stages and require expensive technological equipment, as well as the occurrence of relapses and side effects. Furthermore, the known arrangement does not provide directional complex impact on the whole body to ensure activation of the processes of self-regulation and self-healing.

The objective of the invention is to provide pharmaceutical compositions for the treatment of gastric ulcer and/or duodenal ulcers with high therapeutic effect is azulene ulcer, the absence of recurrence and side effects.

The technical result of the invention is to provide comprehensive effects on the body, promotes faster healing of the mucosal defect with acute peptic ulcer of the stomach and/or duodenal ulcer and prevent recurrence, including at the expense of eradication impact. Complex effect, according to the authors of the invention, is manifested in the form of direct or indirect immunomodulatory, antiviral, antibacterial, anti-inflammatory, antioxidant and regenerating effect.

To achieve the technical result of the pharmaceutical composition for treating gastric ulcer and/or duodenal ulcers in the form of tablets, capsules or gel containing medicines and acceptable for every form of composition consistantness basis, according to the invention as a drug contains recombinant interferon selected from the group: recombinant interferon-alpha, interferon-beta, interferon-gamma; antiseptics; amino acids selected from the group: arginine, histidine, lysine, cysteine, methionine, glutamic acid, and antioxidants selected from the group of: beta-carotene, vitamin C, vitamin E, trace the next ratio of components in g per 1 g of a mixture of:

recombinant interferon, ME1000-10000000
antisepticswithin 0.00001 to 0.5
amino acidswithin 0.00001 to 0.5
antioxidantswithin 0.00001 to 0.5
consistentread baserest

The pharmaceutical composition contains antiseptics selected from the group: lysozyme, bilateral, fusafungine, Amazon, benzyldimethyl-myristoylation-Propylamine, co-trimoxazole, amylmetacresol, dichlorobenzoyl alcohol, cetylpyridinium chloride, benzocaine chloride in a quantity within 0.00001 to 0.5, Can be used and other well-known antiseptics for internal administration.

In addition, the pharmaceutical composition may further comprise glycyrrhizinic acid or its salts in a quantity within 0.00001 to 0.5,

In addition, the pharmaceutical composition may further contain lecithin in the amount within 0.00001 to 0.5,

In addition, the pharmaceutical composition may contain dioxotetrahydrofuran in number within 0.00001 to 0.5,

In addition, the pharmaceutical composition may further contain b vitamins: B1, B2, B3, B, B6, B9, B12 in the amount within 0.00001 to 0.5,

The present invention is illustrated with specific examples of implementation, which, however, are not only possible, but clearly demonstrate the possibility of achieving the purpose and the technical result.

Example 1. Getting a tablet form. Take interferon selected from the group of recombinant interferon-alpha, interferon-beta, interferon-gamma, antiseptics selected from the group: lysozyme, bilateral, fusafungine, Amazon, benzyldimethyl-myristoylation-Propylamine, co-trimoxazole, amylmetacresol, dichlorobenzoyl alcohol, cetylpyridinium chloride, menoxenia chloride; amino acids selected from the group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; antioxidants-vitamins selected from the group of: beta-carotene, vitamin C, vitamin E.

Mix these components with acceptable for this form consistentarea basis and tabletirujut mixture in a known manner.

These components take the following ratio of components in g per 1 g of a mixture of:

option 1option 2Option 3
recombinant int is Heron, ME1001000010000000
antiseptics0,0010,000010,5
amino acids0,000010,0010,5
antioxidants0,000010,0010,5
consistentread basethe rest is up to 1 g

Example 2. Carried out analogously to example 1. Additionally, the composition of the claimed compositions include glycyrrhizinic acid or its salts in a quantity within 0.00001 to 0.5,

Example 3. Carried out analogously to example 1. Additionally, the composition of the claimed compositions include lecithin in the amount within 0.00001 to 0.5,

Example 4. Carried out analogously to example 1. Additionally, the composition of the claimed compositions include the b vitamins: B1, B2, B3, B5, B6, B9, B12 in the amount within 0.00001 to 0.5,

Example 5. Carried out analogously to example 1. Additionally, the composition of the claimed compositions include dioxotetrahydrofuran in number within 0.00001 to 0.5,

According to the authors of the invention with known properties of each separately what about the component can be considered, the proposed pharmaceutical composition possesses immunomodulatory, antiviral, antibacterial, anti-inflammatory, antioxidant and regenerating effect on the human body that lies at the basis of established clinical trials antiulcer effect of this composition. It is known that the anti-inflammatory effect of interferon indirectly connected with its immunobullous effect, as well as the ability of interferon to adjust the sensitivity of cells to cytokines, the expression on cell membranes, activated corticosteroid system, to suppress the reproduction of viruses, i.e., to suppress infection. Various types of interferons in one way or another have the same or a different effect on these mechanisms. Therefore, the presence in the composition of this or that specified in the formula interferon is useful from the point of view of impact on the pathogenesis of peptic ulcer. In addition, antibacterial, antioxidant, local immunomodulatory effect of other active ingredients, along with the effects of interferon, also indirectly affects the activation of sanogenesis in the body, reducing the symptoms of inflammation and providing regenerative activity of tissues. Because peptic ulcer disease, including its pathogenesis, is a common disease is organisma, these direct and indirect effects, according to the authors of inventions, ultimately, lead to the healing of the ulcer in the period of exacerbation.

Use of the claimed pharmaceutical compositions for the treatment of patients with peptic ulcer disease of stomach and duodenum allows for 2-3 weeks to achieve complete cicatrization of the ulcer patients. Therapeutic effectiveness is 100%. The treatment with the claimed pharmaceutical compositions effective for all forms of localization of ulcers and allows to achieve complete healing of ulcers in a short time. Use of the claimed pharmaceutical composition also allows you to prevent recurrence, in this regard, patients retained the ability to work over a long period.

Was treated patients, volunteers, constituents 2 groups of 10 people each, suffering from gastric ulcer and duodenal ulcer in the acute stage. Were monomachine proposed composition (1 tablet or capsule 3 times a day) against a home or a stationary mode and the appropriate diet. On the third day, patients noted a falling, and then the disappearance of the hungry and night pain. On the fourth day of the disappeared dry mouth, stopping heartburn, feeling cages and in the stomach. Normalized stool. Marked improvement in General condition and well-being, appetite. By the end of the third week in these patients spent a gastroscopic examination. Ulcers completely healed. During the inspection there were no complaints. Clinical symptoms of the disease there. Side effects of treatment were noted. Dynamic observation of patients within 1.5-2 years confirmed the efficacy of treatment, recurrence was not observed.

It is known that Helicobacter pylori (Helicobacter pylori) is important in the development of peptic ulcer disease, including in the development of the disease, so the study of the dynamics of indicators of H. pylori activity was also interest in establishing antiulcer efficacy of the claimed composition.

In 12 patients a study of infection before and after treatment. Taken at biopsy tissue mucosa were subjected to testing for the presence of urease and antigens of H. pylori infection, histological examination, and cultural research with the release of the pathogen on artificial nutrient media. Before treatment all the patients showed a high level of infection. After the eradication treatment effect noted in all cases. Although the authors do not have information about H. pylori direct effect of each component HDMI is tion separately our data indicate that a complex effect on the body triggers the processes of sanogenesis that provide suppression of infection. Therefore, understandable results dynamic observation of patients, who underwent treatment of the claimed composition, namely a sufficiently long-term remission of the disease, since it is known that, despite the anti-ulcer treatment in the absence of the effect of eradication, the disease had anticipated.

Thus, a pharmaceutical composition for treating gastric ulcer and/or duodenal ulcers has effective properties ensuring a complex effect on the mechanisms ulcerogenesis and on the whole body, which contributes to the effective treatment of acute gastric ulcer and duodenal ulcer and prevention of relapse in the absence of side effects of treatment.

1. Pharmaceutical composition for treating gastric ulcer and/or duodenal ulcers in the form of tablets, capsules or gel containing medicines and acceptable for every form of composition consistantness base, characterized in that the quality of medicines contains recombinant interferon selected from the group: recombinant the th interferon-alpha, recombinant interferon-beta, interferon-gamma; antiseptics; amino acids selected from the group: arginine, histidine, lysine, cysteine, methionine, glutamic acid, and antioxidants selected from the group of: beta-carotene, vitamin C, vitamin E, in the following ratio of components in g per 1 g of a mixture of:

recombinant interferon IU1000-10000000
antisepticswithin 0.00001 to 0.5
amino acidswithin 0.00001 to 0.5
antioxidantswithin 0.00001 to 0.5
consistentread baserest

2. The pharmaceutical composition under item 1, characterized in that it contains antiseptics selected from the group: lysozyme, bilateral, fusafungine, Amazon, benzyldimethyl-myristoylation-Propylamine, co-trimoxazole, amylmetacresol, dichlorobenzoyl alcohol, cetylpyridinium chloride, benzocaine chloride in a quantity within 0.00001 to 0.5,

3. The pharmaceutical composition under item 1, characterized in that it further contains glycyrrhizinic acid or its salts in a quantity within 0.00001 to 0.5,

4. The pharmaceutical composition under item 1, characterized in that h is about further comprises lecithin in the amount within 0.00001 to 0.5,

5. The pharmaceutical composition under item 1, characterized in that it further comprises dioxotetrahydrofuran in number within 0.00001 to 0.5,

6. The pharmaceutical composition under item 1, characterized in that it further contains b vitamins: B1, B2, B3, B5, B6, B9, B12 in the amount within 0.00001 to 0.5,



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.

EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.

7 cl, 1 ex

FIELD: food industry.

SUBSTANCE: biologically active food additive strengthening the organism adaptive power and body defences and having anti-inflammatory and antioxidant activity contains vegetal origin components represented by a complex extract of devil's-club root, Rhaponticum carthamoides root, Hedysarum neglectum Ledeb root, celery roots and leaves, rhodiola rosea root, Japanese angelica tree roots, boschniakia rossica roots, Hungarian sainfoin herb, magnolia-vine fruits; additionally the additive contains chitosan, trepang fermentative hydrolysate, ascorbic acid, taurine, glutathione, nicotinamide, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, anhydrous calcium chloride, magnesium chloride, zinc chloride, bee honey at preset ingredients ratio.

EFFECT: biologically active food additive promotes effective strengthening of the organism adaptive power and body defences and human aging retardation.

4 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medical radiology and can be used for prevention of cerebral form of acute radiation sickness. Claimed is application of officinal drug pyrazinamide as medication for prevention of cerebral form of acute radiation sickness. Pyrazinamide has been used for treating tuberculosis.

EFFECT: preventing in 100% of cases development of early temporary incapacity in case of irradiation in dose 200 Gy, improvement of indices of behavioral and research activities in irradiated animals, in reduction of frequency of motor disorders, reduction of frequency and expression of convulsive-hyperkinetic syndrome and 9,5 fold increase of average life expectancy of irradiated animals Pyrazinamide is not inferior to drug - nicotinamide prototype in efficiency of radioprotective action.

4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and represents a composition possessing the antioxidant and antibacterial activity and containing lithium ascorbate, differing by the fact that it additionally contains lithium benzoate in the following proportions, wt %: lithium ascorbate - 50; lithium benzoate - 50.

EFFECT: invention provides extending the range of antioxidants with antibacterial activity possessing normothymic activity.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: method for increasing the antitoxic body function in healthy individuals occupied in the chemical load environment involving administering an antioxidant water containing carrot juice, cod liver oil, olive oil, honey; the water is taken daily before the working shift for 10 days.

EFFECT: using the invention enhances the antitoxic body function by administering the water having high antioxidant properties.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is described is using a pharmaceutical composition in the form of an orally disintegrated tablet containing 6-methyl-2-ethyl-3-hydroxypyridine succinate as an active substance and crospovidone as a disintegrating agent in ratio 2:1 respectively, as a motor stimulating and anorectic agent.

EFFECT: preparing motor stimulating and anorectic agent.

16 dwg, 34 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: for the purpose of post-surgical treatment of cerebral tumours, memantine is prescribed in a dose of 10 mg daily for 5-7 days before radiation therapy, and in a dose of 20 mg during radiation therapy 4-6 hours before the radiation session. On completing the course of radiation therapy, memantine is prescribed in patients aged up to 60 years old in a dose of 10 mg for 2-3 months daily, in patients aged 60 and older in a dose of 20 mg for 5-6 months daily.

EFFECT: method enables providing the higher patients' quality of life with a view to cancellation of glucocorticoids, ensuring higher clinical effectiveness ensured by an increase of the medullary substance to radiation.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to an agent with an antidyslipidemic and analgesic effect. The method for preparing the phytocomplex with the antidyslipidemic and analgesic effect, involving: a) grinding peeled bergamot fruit to prepare an undegraded mixture, b) introducing pectinolytic enzymes into the mixture; c) reducing pulp content; d) inactivating the above enzymes added at the stage b), to prepare a degraded mixture; e) performing ultrafiltration of the degraded mixture through membranes isolating the substances having a molecular weight of over 30,000 Da, to prepare a transparent solution; f) introducing the transparent solution on a polyphenol absorption column; g) washing the polyphenol absorption column with water and increasing pH to prepare an aqueous polyphenol fraction; h) transmitting the aqueous polyphenol fraction to cationic resin to recover the phytocomplex in an aqueous phase; i) drying the phytocomplex in the aqueous phase. The phytocomplex in the aqueous phase with the antidyslipidemic and analgesic effect. The phytocomplex with the antidyslipidemic and analgesic effect. A pharmaceutical composition with the antidyslipidemic effect containing the phytocomplex, and pharmaceutically acceptable additives. A pharmaceutical composition with the analgesic effect containing the phytocomplex, and pharmaceutically acceptable additives.

EFFECT: phytocomplex described above possesses the evident antidyslipidemic and analgesic effect.

11 cl

FIELD: medicine.

SUBSTANCE: method involves preliminary intraperitoneal single administration of 5% aqueous alloxan in a dose of 15 mg/kg of body weight into a rat's body on an empty stomach. That is followed by administering afobazol under conditions of oxidative stress after observing the rat's blood glucose gain at least twice. Afobazol is administered subcutaneously in a dose of 10 mg/kg of body weight once a day for 30 days with underlying administration of L-arginine in a dose of 10 mg/kg of body weight or with underlying NG-nitroarginine methyl ester (L-NAME)-inhibitor of NOS-3 enzyme in a dose of 25 mg/kg of animal's weight.

EFFECT: method enables correcting the oxidative stress and NO-producing endothelial dysfunction accompanying vascular complications of diabetes mellitus.

1 dwg, 6 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns an antioxidant representing the amino acid glycine immobilised on the detonation-synthesised nanodiamond particles of 2-10 nm in size.

EFFECT: higher efficacy.

4 cl, 5 dwg, 7 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000.

EFFECT: invention provides a pharmaceutical composition in the form of an ointment, which is new in mechanism of action, effective when applied topically at low therapeutic concentration.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.

EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.

7 cl, 1 ex

FIELD: medicine.

SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.

EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.

3 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: present invention refers to medicine. The preparation contains the active substance furacilin (nitrofural, 2-[(5-nitro-2-furanyl)methylen]hydrazine carboxamide), the excipient - sodium chloride, a gas-forming mixture, an acidity regulator for reducing pH from 6.5 to 7.5 and a lubricant if needed. The gas-forming mixture consists of an organic acid and sodium hydrocarbonate. According to the method for preparing effervescent tablets of furacilin, furacilin and sodium chloride are milled in a combination; all the ingredients are placed into a mixer, and the prepared mixture is tabletted by direct compression. The antimicrobial therapeutic preparation of furacilin in the form of effervescent tablets is used for septic wounds, bed sores, small skin damages, including scratch marks, abrasions, cuts; infectious-inflammatory oral and throat diseases, including acute tonsillitis, stomatitis, gingivitis and tonsillitis. The effervescent tablets of furacilin are storage-stable for two years and water-soluble at room temperature for 5 minutes.

EFFECT: preparing the antimicrobial therapeutic preparation in the form of the effervescent tablets used for preparing the solution for local and external application.

4 cl, 6 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: biologically active additive Laviocard+ is prescribed orally 1 capsule 2 times a day with food for 21 days. That is combined with daily wound irrigations with neutral analyte of anhydrohexitol nucleic acid with leaving a sterile gauze bandage impregnated with neutral analyte of anhydrohexitol nucleic acid in the wound until it is clean. That is followed by daily bandaging with Lavitol cosmetic dihydroquercetin powder applied on the wound surface 1-2 mm thick until the wound is healed.

EFFECT: reduced length of wound healing by stimulating the regeneration processes in tissues.

1 ex, 3 tbl

FIELD: chemistry.

SUBSTANCE: inorganic clay, represented by sodium-calcium, and/or calcium and/or ferrous forms of montmorillonite, is modified with a water solution of silver nitrate with a concentration 0.16-9.9 wt % in a weight ratio clay:water solution of silver nitrate 1:5. Modification is carried out with mixing from 3 to 7 hours at a temperature in the interval from 10°C to the temperature of boiling. The obtained material is washed with distilled water to pH ≈6-5, until excess of silver nitrate is removed, stood at room temperature and decanted. The material is dried at a temperature of 20-160°C.

EFFECT: obtaining an efficient antibacterial material for traditional and veterinary medicine.

2 tbl, 5 ex

FIELD: veterinary medicine.

SUBSTANCE: agent for prevention of mastitis in dairy cows in the dry period, characterised in that it contains as ingredients the polymer PVP/VA, silicone, polyhexamethylene biguanide, ethyl alcohol, glycerol - as emollient component, gelation agents - triethanolamine and carbopol and purified water in the following ratio of ingredients, %: polymer PVP/VA 9-10; silicone 5-6; ethyl alcohol 35-40; polyhexamethylene biguanide 0.008-0.01; glycerol 5; gelation agents - triethanolamine and carbopol 0.1; purified water - the rest.

EFFECT: method enables to minimise or eliminate the use of chemotherapeutic agents, antibiotics and their derivatives, sulphonamides, nitrofurans and eliminate the side effect of the agent on animal body, as well as to reduce the number of visits of the veterinarian during the dry period of cows, to improve the preventive efficacy.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to the veterinary science, particularly to substances used in treating purulent-necrotic involvements of bovine's distal extremities, including digital dermatitis. A preparation for treating bovine digital dermatitis in the form of an ointment consists of an excipient, containing an ointment base, and an active ingredient - zinc oxide and copper sulphate in the following proportions, wt %: zinc oxide 9-11, copper sulphate 35-45, the ointment base - the rest.

EFFECT: invention provides higher clinical effectiveness with cost cutting for the ointment preparation.

1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be used for the preoperative preparation of the patients suffering a perforated nasal septum. Intranasal silicone splints are placed 10 days before the operation. The splint is incised from one side within a perforation border. A 30° endoscope is used to assist a 7-day daily nasal perforation rinsing with chlorhexidine. A suction unit is used to evacuate mucosal secretion; synthomycin ointment is introduced through the incision in the silicone splint to the perforation region. The nasal cavity is irrigated daily with antiseptic and vasoconstrictive preparations. On the 7th day, the intranasal splints are removed.

EFFECT: method enables relieving the mucosal inflammation within the perforation, promotes the prolonged drug retention in the introduction place, ensures avoiding an overlay of a secondary infection, improves the functional state of ciliated epithelium.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgical dentistry and maxillofacial surgery, and is applicable in maxillary sinusotomy with fistula repair. A mucous membrane is incised to a bone under an intubation narcosis after a two-fold preparation of a surgical area. A D-shaped flap is cut out within an alveolar socket of an extracted tooth to be extended along a mucobuccal fold of an upper jaw on one side to a second incisor, and on the other side - to a third molar. The flap together with the periosteum is separated and retracted upwards with exposing a canine fossa and the alveolar socket of the extracted tooth. A hole is created within the canine fossa. Pathologically changed tissues or all sinus mucosa is scooped with a bone curette through the created hole. The alveolar socket of the extracted tooth is inspected. After the cavity has been scooped, an artificial hole is created towards a nasal cavity through an inferior nasal meatus. The sinus cavity is packed with a iodoform cotton swab; an end of the cotton swab is laid thoroughly on a sinus bottom, namely within the defect; the end of the cotton swab is brought out into a nose. A mucoperiosteal flap is mobilised within the alveolar socket of the extracted tooth, laid on the alveolar socket; the wound is closed completely. In the postoperative period, the cotton swab is removed from the sinus on the 9-10th day. The sutures are removed on the 10-11th day.

EFFECT: method enables reducing an incidence of recurrent oroantral communications in the postoperative period ensured by a compact packing of the sinus, and the antiseptic and regeneration effect of iodoform on the maxillary sinus.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a tabletted multiunit dosage form containing an active substance specified in a compound of N+K+ATPhase inhibitor, one its individual enantiomer and its alkaline salt, wherein individually enteric-coated units of a nuclear material containing the active substance optionally mixed with alkaline compounds, is mixed with tablet excipients and tabletted. The enteric coating is at least 10 mcm thick and has such mechanical properties that tabletting the individual units mixed with the excipients in the multiunit tabletted dosage form does not reduce the acid stability of the enteric coated units by more than 10%. The invention also refers to a method for preparing the multiunit dosage form, according to which the material units containing the active substance are mixed whenever necessary with the alkaline compounds; then these can be coated with separate layers; the enteric coating is applied, mixed with the excipients and tabletted.

EFFECT: what is declared is a method for inhibiting gastric acid secretion or treating gastrointestinal diseases in mammals and humans by administering a therapeutically effective dose of the multiunit tabletted dosage form.

17 cl, 2 tbl, 19 ex

Up!